Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial.

Jankovic J, Goodman I, Safirstein B, Marmon TK, Schenk DB, Koller M, Zago W, Ness DK, Griffith SG, Grundman M, Soto J, Ostrowitzki S, Boess FG, Martin-Facklam M, Quinn JF, Isaacson SH, Omidvar O, Ellenbogen A, Kinney GG.

JAMA Neurol. 2018 Jun 18. doi: 10.1001/jamaneurol.2018.1487. [Epub ahead of print]

PMID:
29913017
2.

Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting.

Walsh RR, Krismer F, Galpern WR, Wenning GK, Low PA, Halliday G, Koroshetz WJ, Holton J, Quinn NP, Rascol O, Shaw LM, Eidelberg D, Bower P, Cummings JL, Abler V, Biedenharn J, Bitan G, Brooks DJ, Brundin P, Fernandez H, Fortier P, Freeman R, Gasser T, Hewitt A, Höglinger GU, Huentelman MJ, Jensen PH, Jeromin A, Kang UJ, Kaufmann H, Kellerman L, Khurana V, Klockgether T, Kim WS, Langer C, LeWitt P, Masliah E, Meissner W, Melki R, Ostrowitzki S, Piantadosi S, Poewe W, Robertson D, Roemer C, Schenk D, Schlossmacher M, Schmahmann JD, Seppi K, Shih L, Siderowf A, Stebbins GT, Stefanova N, Tsuji S, Sutton S, Zhang J.

Neurology. 2018 Jan 9;90(2):74-82. doi: 10.1212/WNL.0000000000004798. Epub 2017 Dec 13. Review.

PMID:
29237794
3.

Sorting Through the Spheres of Influence: Using Modified Pile Sorting to Describe Who Influences Dairy Farmers' Decision-Making About Safety.

Bendixsen C, Barnes K, Kieke B, Schenk D, Simich J, Keifer M.

J Agromedicine. 2017;22(4):316-327. doi: 10.1080/1059924X.2017.1353938.

PMID:
28715252
4.

Amplification of overlapping DNA amplicons in a single-tube multiplex PCR for targeted next-generation sequencing of BRCA1 and BRCA2.

Schenk D, Song G, Ke Y, Wang Z.

PLoS One. 2017 Jul 12;12(7):e0181062. doi: 10.1371/journal.pone.0181062. eCollection 2017.

5.

Evidence for transcriptome-wide RNA editing among Sus scrofa PRE-1 SINE elements.

Funkhouser SA, Steibel JP, Bates RO, Raney NE, Schenk D, Ernst CW.

BMC Genomics. 2017 May 9;18(1):360. doi: 10.1186/s12864-017-3766-7.

6.

Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy.

Spencer B, Valera E, Rockenstein E, Overk C, Mante M, Adame A, Zago W, Seubert P, Barbour R, Schenk D, Games D, Rissman RA, Masliah E.

Acta Neuropathol Commun. 2017 Jan 13;5(1):7. doi: 10.1186/s40478-016-0410-8.

7.

First-in-human assessment of PRX002, an anti-α-synuclein monoclonal antibody, in healthy volunteers.

Schenk DB, Koller M, Ness DK, Griffith SG, Grundman M, Zago W, Soto J, Atiee G, Ostrowitzki S, Kinney GG.

Mov Disord. 2017 Feb;32(2):211-218. doi: 10.1002/mds.26878. Epub 2016 Nov 25.

8.

2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis .

Renz M, Torres R, Dolan PJ, Tam SJ, Tapia JR, Li L, Salmans JR, Barbour RM, Shughrue PJ, Nijjar T, Schenk D, Kinney GG, Zago W.

Amyloid. 2016 Sep;23(3):168-177. Epub 2016 Aug 5.

9.

Evaluation of C18 monolithic columns for radiochemical purity measurement.

Schenk DJ, Welch CJ, Antonucci V.

J Labelled Comp Radiopharm. 2016 Aug;59(10):391-7. doi: 10.1002/jlcr.3422. Epub 2016 Jul 13.

PMID:
27411721
10.

Preclinical Characterization of 18F-MK-6240, a Promising PET Tracer for In Vivo Quantification of Human Neurofibrillary Tangles.

Hostetler ED, Walji AM, Zeng Z, Miller P, Bennacef I, Salinas C, Connolly B, Gantert L, Haley H, Holahan M, Purcell M, Riffel K, Lohith TG, Coleman P, Soriano A, Ogawa A, Xu S, Zhang X, Joshi E, Della Rocca J, Hesk D, Schenk DJ, Evelhoch JL.

J Nucl Med. 2016 Oct;57(10):1599-1606. Epub 2016 May 26.

11.

Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs).

Walji AM, Hostetler ED, Selnick H, Zeng Z, Miller P, Bennacef I, Salinas C, Connolly B, Gantert L, Holahan M, O'Malley S, Purcell M, Riffel K, Li J, Balsells J, OBrien JA, Melquist S, Soriano A, Zhang X, Ogawa A, Xu S, Joshi E, Della Rocca J, Hess FJ, Schachter J, Hesk D, Schenk D, Struyk A, Babaoglu K, Lohith TG, Wang Y, Yang K, Fu J, Evelhoch JL, Coleman PJ.

J Med Chem. 2016 May 26;59(10):4778-89. doi: 10.1021/acs.jmedchem.6b00166. Epub 2016 May 5.

PMID:
27088900
12.

Determining the isotopic abundance of a labeled compound by mass spectrometry and how correcting for natural abundance distribution using analogous data from the unlabeled compound leads to a systematic error.

Schenk DJ, Lockley WJ, Elmore CS, Hesk D, Roberts D.

J Labelled Comp Radiopharm. 2016 Apr;59(4):136-46. doi: 10.1002/jlcr.3370. Epub 2016 Feb 24.

PMID:
26916110
13.

First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.

Gertz MA, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, Merlini G, Schönland S, Walling J, Kinney GG, Koller M, Schenk DB, Guthrie SD, Liedtke M.

J Clin Oncol. 2016 Apr 1;34(10):1097-103. doi: 10.1200/JCO.2015.63.6530. Epub 2016 Feb 8.

14.

A Tool for Providing Data on Small Areas: Development of Neighborhood Profiles for Santa Clara County, California, 2014.

Webber WL, Stoddard P, van Erp B, Baath M, Bazhaw G, Kelsey K, Schenk D, Shah R, Shoe B, Sujeer A.

Public Health Rep. 2016 Jan-Feb;131(1):35-43.

15.

Stimulation with bone morphogenetic protein-2 (BMP-2) enhances bone-tendon integration in vitro.

Schwarting T, Schenk D, Frink M, Benölken M, Steindor F, Oswald M, Ruchholtz S, Lechler P.

Connect Tissue Res. 2016;57(2):99-112. doi: 10.3109/03008207.2015.1087516. Epub 2015 Nov 11.

PMID:
26558768
16.

Identification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for Tauopathies.

Pickhardt M, Neumann T, Schwizer D, Callaway K, Vendruscolo M, Schenk D, St George-Hyslop P, Mandelkow EM, Dobson CM, McConlogue L, Mandelkow E, Tóth G.

Curr Alzheimer Res. 2015;12(9):814-28.

17.

Renal and Adrenal Ultrasonography: a valuable diagnostic tool in the salt-wasting infant.

Reynolds BC, Schenk D, Kambalimath M, Jackson M, Cheetham T.

Acta Paediatr. 2016 Feb;105(2):e85-8. doi: 10.1111/apa.13217. Epub 2015 Nov 4.

PMID:
26384151
18.

Site selective syntheses of [(3)H]omeprazole using hydrogen isotope exchange chemistry.

Pollack SR, Schenk DJ.

J Labelled Comp Radiopharm. 2015 Sep-Oct;58(11-12):433-41. doi: 10.1002/jlcr.3346. Epub 2015 Sep 18.

PMID:
26380956
19.

NMR-based approach to the analysis of radiopharmaceuticals: radiochemical purity, specific activity, and radioactive concentration values by proton and tritium NMR spectroscopy.

Schenk DJ, Dormer PG, Hesk D, Pollack SR, Lavey CF.

J Labelled Comp Radiopharm. 2015 Jun 15;58(7):291-8. doi: 10.1002/jlcr.3295. Epub 2015 May 26.

PMID:
26014438
20.

Application of HPLC mixed-mode chromatography in determining radiochemical purity of [(14) C] labeled metformin hydrochloride.

Truong V, Helmy R, Ren S, Schenk D, Waterhouse D.

J Labelled Comp Radiopharm. 2015 Apr;58(4):177-9. doi: 10.1002/jlcr.3264. Epub 2015 Feb 27.

PMID:
25720824
21.

Evaluation of UV-HPLC and mass spectrometry methods for specific activity determination.

Elmore CS, Schenk DJ, Arent R, Kingston L.

J Labelled Comp Radiopharm. 2014 Sep;57(11):645-51. doi: 10.1002/jlcr.3234. Epub 2014 Sep 16.

PMID:
25223538
22.

Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab.

Feinberg H, Saldanha JW, Diep L, Goel A, Widom A, Veldman GM, Weis WI, Schenk D, Basi GS.

Alzheimers Res Ther. 2014 Jun 2;6(3):31. doi: 10.1186/alzrt261. eCollection 2014.

23.

Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.

Games D, Valera E, Spencer B, Rockenstein E, Mante M, Adame A, Patrick C, Ubhi K, Nuber S, Sacayon P, Zago W, Seubert P, Barbour R, Schenk D, Masliah E.

J Neurosci. 2014 Jul 9;34(28):9441-54. doi: 10.1523/JNEUROSCI.5314-13.2014.

24.

β-Amyloid inhibits E-S potentiation through suppression of cannabinoid receptor 1-dependent synaptic disinhibition.

Orr AL, Hanson JE, Li D, Klotz A, Wright S, Schenk D, Seubert P, Madison DV.

Neuron. 2014 Jun 18;82(6):1334-45. doi: 10.1016/j.neuron.2014.04.039.

25.

Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease.

Tóth G, Gardai SJ, Zago W, Bertoncini CW, Cremades N, Roy SL, Tambe MA, Rochet JC, Galvagnion C, Skibinski G, Finkbeiner S, Bova M, Regnstrom K, Chiou SS, Johnston J, Callaway K, Anderson JP, Jobling MF, Buell AK, Yednock TA, Knowles TP, Vendruscolo M, Christodoulou J, Dobson CM, Schenk D, McConlogue L.

PLoS One. 2014 Feb 14;9(2):e87133. doi: 10.1371/journal.pone.0087133. eCollection 2014. Erratum in: PLoS One. 2014;9(5):e99274.

26.

Kinetics and Mechanistic Studies on the Reaction between Cytochrome c and Tea Catechins.

Wang L, Santos E, Schenk D, Rabago-Smith M.

Antioxidants (Basel). 2014 Aug 19;3(3):559-68. doi: 10.3390/antiox3030559.

27.

Chronic γ-secretase inhibition reduces amyloid plaque-associated instability of pre- and postsynaptic structures.

Liebscher S, Page RM, Käfer K, Winkler E, Quinn K, Goldbach E, Brigham EF, Quincy D, Basi GS, Schenk DB, Steiner H, Bonhoeffer T, Haass C, Meyer-Luehmann M, Hübener M.

Mol Psychiatry. 2014 Aug;19(8):937-46. doi: 10.1038/mp.2013.122. Epub 2013 Sep 24.

28.

Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease.

Gardai SJ, Mao W, Schüle B, Babcock M, Schoebel S, Lorenzana C, Alexander J, Kim S, Glick H, Hilton K, Fitzgerald JK, Buttini M, Chiou SS, McConlogue L, Anderson JP, Schenk DB, Bard F, Langston JW, Yednock T, Johnston JA.

PLoS One. 2013 Aug 23;8(8):e71634. doi: 10.1371/journal.pone.0071634. eCollection 2013.

29.

Identification of small-molecule binding pockets in the soluble monomeric form of the Aβ42 peptide.

Zhu M, De Simone A, Schenk D, Toth G, Dobson CM, Vendruscolo M.

J Chem Phys. 2013 Jul 21;139(3):035101. doi: 10.1063/1.4811831.

30.

Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide.

Verwey NA, Hoozemans JJ, Korth C, van Royen MR, Prikulis I, Wouters D, Twaalfhoven HA, van Haastert ES, Schenk D, Scheltens P, Rozemuller AJ, Blankenstein MA, Veerhuis R.

Amyloid. 2013 Sep;20(3):179-87. doi: 10.3109/13506129.2013.797389. Epub 2013 Jul 5.

PMID:
23829200
31.

Beyond amyloid: getting real about nonamyloid targets in Alzheimer's disease.

Herrup K, Carrillo MC, Schenk D, Cacace A, Desanti S, Fremeau R, Bhat R, Glicksman M, May P, Swerdlow R, Van Eldik LJ, Bain LJ, Budd S.

Alzheimers Dement. 2013 Jul;9(4):452-458.e1. doi: 10.1016/j.jalz.2013.01.017.

32.

Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities.

Zago W, Schroeter S, Guido T, Khan K, Seubert P, Yednock T, Schenk D, Gregg KM, Games D, Bard F, Kinney GG.

Alzheimers Dement. 2013 Oct;9(5 Suppl):S105-15. doi: 10.1016/j.jalz.2012.11.010. Epub 2013 Apr 11.

PMID:
23583235
33.

Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein.

Games D, Seubert P, Rockenstein E, Patrick C, Trejo M, Ubhi K, Ettle B, Ghassemiam M, Barbour R, Schenk D, Nuber S, Masliah E.

Am J Pathol. 2013 Mar;182(3):940-53. doi: 10.1016/j.ajpath.2012.11.018. Epub 2013 Jan 9.

34.

AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils.

Wall JS, Kennel SJ, Williams A, Richey T, Stuckey A, Huang Y, Macy S, Donnell R, Barbour R, Seubert P, Schenk D.

PLoS One. 2012;7(12):e52686. doi: 10.1371/journal.pone.0052686. Epub 2012 Dec 26.

35.

Advancing Alzheimer's disease diagnosis, treatment, and care: recommendations from the Ware Invitational Summit.

Naylor MD, Karlawish JH, Arnold SE, Khachaturian AS, Khachaturian ZS, Lee VM, Baumgart M, Banerjee S, Beck C, Blennow K, Brookmeyer R, Brunden KR, Buckwalter KC, Comer M, Covinsky K, Feinberg LF, Frisoni G, Green C, Guimaraes RM, Gwyther LP, Hefti FF, Hutton M, Kawas C, Kent DM, Kuller L, Langa KM, Mahley RW, Maslow K, Masters CL, Meier DE, Neumann PJ, Paul SM, Petersen RC, Sager MA, Sano M, Schenk D, Soares H, Sperling RA, Stahl SM, van Deerlin V, Stern Y, Weir D, Wolk DA, Trojanowski JQ.

Alzheimers Dement. 2012 Sep;8(5):445-52. doi: 10.1016/j.jalz.2012.08.001.

36.

Treatment strategies targeting amyloid β-protein.

Schenk D, Basi GS, Pangalos MN.

Cold Spring Harb Perspect Med. 2012 Sep 1;2(9):a006387. doi: 10.1101/cshperspect.a006387. Review.

37.

Evidence that enzyme processivity mediates differential Aβ production by PS1 and PS2.

Pintchovski SA, Schenk DB, Basi GS.

Curr Alzheimer Res. 2013 Jan;10(1):4-10.

38.

Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice.

Bard F, Fox M, Friedrich S, Seubert P, Schenk D, Kinney GG, Yednock T.

Exp Neurol. 2012 Nov;238(1):38-43. doi: 10.1016/j.expneurol.2012.07.022. Epub 2012 Aug 7.

PMID:
22892246
39.

Which antithyroid drug regimen in paediatric Graves' disease?

Schenk D, Donaldson M, Cheetham T.

Clin Endocrinol (Oxf). 2012 Dec;77(6):806-7. doi: 10.1111/j.1365-2265.2012.04509.x. No abstract available.

PMID:
22816522
40.

The spectrum of 4q- syndrome illustrated by a case series.

Strehle EM, Gruszfeld D, Schenk D, Mehta SG, Simonic I, Huang T.

Gene. 2012 Sep 15;506(2):387-91. doi: 10.1016/j.gene.2012.06.087. Epub 2012 Jul 3.

PMID:
22771923
41.

Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific.

Zago W, Buttini M, Comery TA, Nishioka C, Gardai SJ, Seubert P, Games D, Bard F, Schenk D, Kinney GG.

J Neurosci. 2012 Feb 22;32(8):2696-702. doi: 10.1523/JNEUROSCI.1676-11.2012.

42.

Investigation of CuInS2 thin film formation by a low-temperature chemical deposition method.

Fischereder A, Rath T, Haas W, Amenitsch H, Schenk D, Zankel A, Saf R, Hofer F, Trimmel G.

ACS Appl Mater Interfaces. 2012 Jan;4(1):382-90. doi: 10.1021/am2014579. Epub 2011 Dec 21.

PMID:
22132877
43.

Regulatory assessment of in vitro skin corrosion and irritation data within the European framework: Workshop recommendations.

Eskes C, Detappe V, Koëter H, Kreysa J, Liebsch M, Zuang V, Amcoff P, Barroso J, Cotovio J, Guest R, Hermann M, Hoffmann S, Masson P, Alépée N, Arce LA, Brüschweiler B, Catone T, Cihak R, Clouzeau J, D'Abrosca F, Delveaux C, Derouette JP, Engelking O, Facchini D, Fröhlicher M, Hofmann M, Hopf N, Molinari J, Oberli A, Ott M, Peter R, Sá-Rocha VM, Schenk D, Tomicic C, Vanparys P, Verdon B, Wallenhorst T, Winkler GC, Depallens O.

Regul Toxicol Pharmacol. 2012 Mar;62(2):393-403. doi: 10.1016/j.yrtph.2011.10.015. Epub 2011 Nov 6.

PMID:
22085589
44.

Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease.

Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, Mueller-Steiner S, Seubert P, Barbour R, McConlogue L, Buttini M, Games D, Schenk D.

PLoS One. 2011 Apr 29;6(4):e19338. doi: 10.1371/journal.pone.0019338.

45.

Revision of the criteria for Alzheimer’s disease: A symposium.

DeKosky ST, Carrillo MC, Phelps C, Knopman D, Petersen RC, Frank R, Schenk D, Masterman D, Siemers ER, Cedarbaum JM, Gold M, Miller DS, Morimoto BH, Khachaturian AS, Mohs RC.

Alzheimers Dement. 2011 Jan;7(1):e1-12.

PMID:
21322828
46.

Generation and characterization of anti-AA amyloid-specific monoclonal antibodies.

Wall JS, Kennel SJ, Richey T, Allen A, Stuckey A, Weiss DT, Macy SD, Barbour R, Seubert P, Solomon A, Schenk D.

Front Immunol. 2011 Aug 8;2:32. doi: 10.3389/fimmu.2011.00032. eCollection 2011.

47.

Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease.

Basi GS, Hemphill S, Brigham EF, Liao A, Aubele DL, Baker J, Barbour R, Bova M, Chen XH, Dappen MS, Eichenbaum T, Goldbach E, Hawkinson J, Lawler-Herbold R, Hu K, Hui T, Jagodzinski JJ, Keim PS, Kholodenko D, Latimer LH, Lee M, Marugg J, Mattson MN, McCauley S, Miller JL, Motter R, Mutter L, Neitzel ML, Ni H, Nguyen L, Quinn K, Ruslim L, Semko CM, Shapiro P, Smith J, Soriano F, Szoke B, Tanaka K, Tang P, Tucker JA, Ye XM, Yu M, Wu J, Xu YZ, Garofalo AW, Sauer JM, Konradi AW, Ness D, Shopp G, Pleiss MA, Freedman SB, Schenk D.

Alzheimers Res Ther. 2010 Dec 29;2(6):36. doi: 10.1186/alzrt60.

48.

Metabolism and excretion of [14C]taranabant, a cannabinoid-1 inverse agonist, in humans.

Karanam B, Addy C, Bateman T, Reddy VB, Li S, Dean D, Li H, Jones A, Schenk D, Zhang AS, Braun M, Freeman A, Flach S, Stoch A, Chodakewitz J, Wagner JA, Kumar S.

Xenobiotica. 2010 Oct;40(10):691-700. doi: 10.3109/00498254.2010.509820.

PMID:
20722472
49.

Introduction to the special issue of Experimental Neurology on Alzheimer's disease.

Schenk D.

Exp Neurol. 2010 Jun;223(2):251. doi: 10.1016/j.expneurol.2010.03.012. Epub 2010 Mar 25. No abstract available.

PMID:
20346942
50.

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M.

Lancet Neurol. 2010 Apr;9(4):363-72. doi: 10.1016/S1474-4422(10)70043-0. Epub 2010 Feb 26.

PMID:
20189881

Supplemental Content

Loading ...
Support Center